Dr. Larry Wu
Dr. Larry Wu is an aesthetic practitioner and clinical researcher based in Singapore, focusing on advanced biostimulatory injectables and ultrasound-guided aesthetic medicine. His clinical research has significantly contributed to standardising safety protocols for polycaprolactone (PCL)-based dermal fillers (Ellansé).
Dr. Wu has authored foundational studies on structural rejuvenation, demonstrating the long-term efficacy and high patient satisfaction rates of PCL microspheres in the restoration of upper-facial subunits, such as the forehead and temporal zones (Wu & Wang, 2024).
Concurrently, Dr. Wu has established himself as a global pioneer in the management of non-hyaluronic acid filler complications. To counter the challenging lack of a reliable reversal agent for PCL fillers, his team introduced the iCare Technique, publishing landmark evidence demonstrating the targeted enzymatic degradation of PCL microspheres via a quantified collagenase mixture (Wu, 2025).
His recent publication in the Journal of Cosmetic Dermatology outlines the integration of Point-of-Care Ultrasound (POCUS) for the precision management of Ellansé-treated patients (Wu et al., 2025). This framework advocates for high-frequency ultrasound imaging to differentiate neocollagenesis from overfilling, confirm nodule dissolution, and map altered vascular anatomy (such as the submental or transverse facial arterial septum) prior to treatment. Dr. Wu’s work bridging high-resolution sonography with intralesional therapeutics continues to define the modern standard of care for biostimulator safety.
Stay Updated
Get the latest aesthetic treatment news straight to your inbox